1. Steg G, James DK, Atar D et al. Acute Myocardial Infarction in patients presenting with ST-segment elevation (Management of). Eur Heart J 2012; 33: 2569–619.
2. O’Gara PT, Kushner FG, Ascheim DD et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013: published online before print December 17, 2012; 10.1161/CIR.0b013e3182742c84
3. Hamm CW, Bassand JP, Agewall S et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011; 32: 2999–3054.
4. Wright RS, Anderson JL, Adams CD et al. 2011 ACCF/AHA focused update incorporated into the ACC/AHA2007Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction: a report of the American College of Cardiology Foundation /American Heart Association Task Force on Practice Guidelines developed in collaboration with the American Academy ofFamily Physicians, Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons. J Am Coll Cardiol 2011; 57: e215–367.
5. Thygesen K, Alpert JS, Jaffe AS et al. Joint ESC/ACCF/AHA/WHF Task Force for the Universal Definition of Myocardial Infarction. Third universal definition of myocardial infarction. Circulation 2012; 126: 2020–35.
6. Omland T, Pfeffer MA, Solomon SD et al. Prognostic value of cardiac troponin I measured with a highly sensitive assay in patients with stable coronary artery disease. J Am Coll Cardiol 2013; DOI: 10.1016/j.jacc.2012.12.026
7. De Lemos JA, Drazner MH, Omland T et al. Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. JAMA 2010; 304: 2503–12.
8. Saunders JT, Nambi V, de Lemos JA et al. Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the atherosclerosis risk in communities study. Circulation 2011; 123: 1367–76.
9. Brauwald E, Morrow DA. Unstable Angina: Is It Time for a Requiem? Circulation 2013; 127: 2452–7.
10. Eikelboom JW, Mehta SR, Anand SS et al. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 2006; 114: 774–82.
11. Budaj A, Eikelboom JW, Mehta SR et al. Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes. Eur Heart J 2009; 30: 655–61.
12. Mehran R, Pocock SJ, Stone GW et al. Associations of major bleeding and myocardial infarction with the incidence and timing of mortality in patients presenting with non-ST-elevation acute coronary syndromes: a risk model from the ACUITY trial. Eur Heart J 2009; 30: 1457–66.
13. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group: Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. Lancet 1988; 2: 349–60.
14. Baigent C, Collins R, Appleby et al. ISIS-2: 10 year survival among patients with suspected acute myocardial infarction in randomized comparision of intravenous streptokinase, oral aspirin, both, or neither. BMJ 1998; 316: 1337–43.
15. Cairns JA, Gent M, Singer J et al. Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial. N Engl J Med 1985; 313: 1369–75.
16. The Clopidogrel in Unstable Angina to Prevent Recurrent Events trial investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. New Engl J Med 2001; 345: 494–502.
17. Sabatine MS, Cannon CP, Gibson et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005; 352: 1179–89.
18. COMMIT collaborative group. Addition of clopidogrel to aspirin in 45852 patients with acute myocardial infarction: randomized placebo-controlled trial. Lancet 2005; 366: 1607–21.
19. Wiviott SD, Braunwald E, McCabe CH et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357: 2001–15.
20. Roe MT, Armstrong PW, Fox KA et al. TRILOGY ACS Investigators. Prasugrel versus clopidogrel for the acute coronary syndromes without revascularization. N Engl J Med 2012; 367 (4): 1297–309.
21. Wallentin L, Becker RC, Budaj A et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361. DOI: 10.1056/NEJMoa0904327.
22. Serebruany VL, Atar D. The PLATO trial: do you believe in magic? Eur Heart J 2010; 31: 764–7.
23. DiNicolantonio JJ, Serebruany VL. Exploring the ticagrelor-statin interplay in the PLATO trial. Cardiology 2013; 124: 105–7.
24. Shneider DJ. Mechanisms Potentially contributing to the reduction in Mortality Associated with ticagrelor therapy. J Am Coll Cardiol 2011; 
57 (6): 685–7.

О.В.Аверков

ГБУЗ Городская клиническая больница №15 им. О.М.Филатова Департамента здравоохранения г. Москвы;
ГОУ ВПО Российский университет дружбы народов, Москва